Spain Brazil Russia France Germany China Korea Japan

Artificial Intelligence driven Marketing Communications

Oct 5, 2020 10:10 AM ET

Global Inflammatory Bowel Disease Treatment Market Set for Rapid Growth, to reach Value around USD 20.80 Billion by 2025


iCrowd Newswire - Oct 5, 2020

Zion Market Research has published a new report titled “Inflammatory Bowel Disease Treatment Market by Type (Crohn’s Disease, and Ulcerative Colitis), by Route of Administration (Injectables [TNF-Inhibitors, IL Inhibitors, Anti-integrin, and Others], and Oral [ASAs, Corticosteroids, JAK Inhibitors, and Others]), and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2025”. According to the report, global demand for inflammatory bowel disease treatment market was valued at approximately USD 15.54 billion in 2018, and is expected to generate revenue of around USD 20.80 billion by end of 2025, growing at a CAGR of around 4.3% between 2019 and 2025.

Inflammatory Bowel Disease Treatment Market

IBD or inflammatory bowel disease is mainly caused when the immune system is attacked by bacteria, virus, or food in the intestine. The common types of IBD are ulcerative colitis, and Crohn’s disease. IBD drugs are used in the treatment of autoimmune diseases like indeterminate colitis, Crohn’s disease, and ulcerative colitis. Ulcerative colitis affects large intestine and the anus causing sores and inflammation of the inner lining of colon and rectum. Crohn’s disease affects parts of the gastrointestinal tract unlike ulcerative colitis which affects all the layers of GI walls.

Request Free Sample is Available @ https://www.zionmarketresearch.com/sample/inflammatory-bowel-disease-treatment-market 

Growth in healthcare expenditure by government and private organizations is likely to increase market growth for IBD treatment. Likely, stressful and sedentary lifestyle and rising uptake of unhealthy food and drinks is also boosting the market growth. Besides, surge in the uptake of biosimilars is also one of the other factors overriding the overall market growth for IBD treatment. Biosimilars are also cheaper as compared to biologics, thus making it accessible especially in the under developed countries. Besides, the probable patent expiration for some of the major selling drugs is also among the factors responsible for launch of new biosimilars in the market.

The market for IBD treatment is segmented based on route of administration, type, distribution channel, and regions. On the basis of type the market is segmented into ulcerative colitis and Crohn’s disease. The segment for Crohn’s disease held major share of the market however, the segment for ulcerative colitis is likely to grow at high CAGR in the forecast period due to the presence of strong pipeline products for treatment of this disease, and also the growing involvement of key players in the development of new products related to this field. Based distribution channel the market is segmented into retail pharmacy, online pharmacy, and hospital pharmacy. The segment for hospital pharmacy held major share of the market in 2018.

Based on route of administration the market for IBD treatment is segmented into oral, and injectables. The market for injectables is further segmented into IL inhibitors, anti-integrin, TNF-inhibitors, and others. The segment for oral drugs is further segmented into ASAs, corticosteroids, JAK inhibitors, and others. The segment for injectable drugs held major share of the market in terms of revenue as injectable drugs are considered to show high efficacy rates. Moreover, advent of biosimilars like Inflectra is also likely to fuel this segmental growth in the forecast period.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa with its further bifurcation into major countries. North America held major share of the market in 2018 owing to high prevalence rate of ulcerative colitis, and Crohn’s disease and growing geriatric population base in this region. Moreover, Asia Pacific is likely to be the fastest growing segment in the forecast period.

Some of the players within global IBD treatment market are Mylan Pharmaceuticals Ltd., Takeda Pharmaceutical, Abbott Laboratories, Pfizer, Inc., Sanofi S.A., Biocon Ltd, F. Hoffmann-La Roche AG, Johnson & Johnson, Quest Medical, Inc., and Novartis AG.

This report segments the global inflammatory bowel disease treatment market as follows:

Global Inflammatory Bowel Disease Treatment Market: Type Segment Analysis

Global Inflammatory Bowel Disease Treatment Market: Route of Administration Segment Analysis

Global Inflammatory Bowel Disease Treatment Market: Distribution Channel Segment Analysis

Global Inflammatory Bowel Disease Treatment Market: Regional Segment Analysis

To view TOC of this report is available upon request @ https://www.zionmarketresearch.com/toc/inflammatory-bowel-disease-treatment-market 

 

Related Report:

https://www.zionmarketresearch.com/report/bench-top-dental-autoclaves-market 

https://www.zionmarketresearch.com/report/intrapartum-monitoring-devices-market 



Contact Information:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com






Keywords:    Inflammatory Bowel Disease Treatment Market

Tags:    IPS, iCN Internal Distribution, Research Newswire, English